Skip to main content
VHCP Management EG on Muck Rack

VHCP Management EG

As seen in: StreetInsider, ADVFN, MarketScreener, Quantisnow
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with VHCP Management

Contact VHCP Management, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.

|
By VHCP Management III, Sherman G. Souther, ized Signatory, VHCP Management EG
| StreetInsider
Item 1. (a) Name of issuer: Tenax Therapeutics, Inc. (b) Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, 27517. Item 2.
Open in Who Shared View Duplicates (6) Issue with article?

Form SCHEDULE 13G/A Zura Bio Ltd Filed by: Venrock Healthcare Capital Partners III, L.P.

|
By VHCP Management III, Sherman G. Souther, ized Signatory, VHCP Management EG
| StreetInsider
Item 1. (a) Name of issuer: ZURA BIO LIMITED (b) Address of issuer's principal executive offices: 1489 West Warm Springs Road #110, Henderson, NV, 89014. Item 2.
Open in Who Shared View Duplicates (177) Issue with article?

SEC Form SCHEDULE 13G filed by Oric Pharmaceuticals Inc.

|
By VHCP Management III, Sherman G. Souther, ized Signatory, VHCP Management EG
| Quantisnow
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan into the second half of 2027 and through anticipated primary endpoint readout from first ORIC-944 Phase 3 registrational trial in prostate cancer SOUTH SAN FRANCISCO, Calif.
Open in Who Shared Issue with article?
See all 54 articles